# A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002

> **NCT06162299** · PHASE1 · TERMINATED · sponsor: **Yisheng Biopharma (Singapore) Pte. Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **BIOLOGICAL:** YS-HBV-002

## Key facts

- **NCT ID:** NCT06162299
- **Lead sponsor:** Yisheng Biopharma (Singapore) Pte. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-07-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-10-31
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Business strategy
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06162299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06162299, "A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06162299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*